|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Trade receivables, less allowance for credit losses of $285 as of June 30, 2026 and $242 as of December 31, 2025 | ||||||||||||||||||||
| Trade receivables from related parties | ||||||||||||||||||||
| Inventories | ||||||||||||||||||||
| Insurance receivable - asbestos | ||||||||||||||||||||
| Contract assets | ||||||||||||||||||||
| Estimated recovery - UES-UK (Note 2) | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property, plant and equipment, net | ||||||||||||||||||||
| Operating lease right-of-use assets | ||||||||||||||||||||
| Insurance receivable - asbestos, less allowance for credit losses of $537 as of June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Deferred income tax assets | ||||||||||||||||||||
| Intangible assets, net | ||||||||||||||||||||
| Investments in joint ventures | ||||||||||||||||||||
| Prepaid pensions | ||||||||||||||||||||
| Other noncurrent assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and Shareholders’ Equity | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accounts payable to related parties | ||||||||||||||||||||
| Accrued payrolls and employee benefits | ||||||||||||||||||||
| Debt – current portion | ||||||||||||||||||||
| Operating lease liabilities – current portion | ||||||||||||||||||||
| Asbestos liability – current portion | ||||||||||||||||||||
| Customer-related liabilities | ||||||||||||||||||||
| Other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Employee benefit obligations | ||||||||||||||||||||
| Asbestos liability | ||||||||||||||||||||
| Long-term debt | ||||||||||||||||||||
| Noncurrent operating lease liabilities | ||||||||||||||||||||
| Deferred income tax liabilities | ||||||||||||||||||||
| Other noncurrent liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders’ equity: | ||||||||||||||||||||
| Common stock - par value $1; authorized 40,000 shares; issued and outstanding 20,614 shares as of June 30, 2026 and 20,237 shares as of December 31, 2025 | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Retained deficit | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Total Ampco-Pittsburgh shareholders’ equity | ||||||||||||||||||||
| Noncontrolling interest | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity |
Loading...
